Blood glucose disease management system

A disease management system comprising:

• a blood glucose sensor configured to measure blood glucose data;
• a pose sensor configured for placement on an individual's torso and to provide pose information of the individual;
• a needle;
• an actuator configured to administer glucagon to the individual;
• and
• one or more processors in communication with the blood glucose sensor and the pose sensor and configured reduce a risk of the individual choking in response to administration of glucagon, the one or more processors programmed to:
• determine a pose of the individual based at least in part on the pose information,
• determine a blood glucose measurement based at least in part on the blood glucose data,
• identify a hypoglycemic event of the individual based at least in part on the blood glucose measurement;
• determine whether a status of the individual is a safe treatment status or an unsafe treatment status, wherein the safe treatment status is indicated by the detection of the hypoglycemic event and determination that the pose of the individual is lying on their back, and wherein the unsafe treatment status is indicated by detection of the hypoglycemic event and determination that the pose of the individual is a pose other than lying on their back;
• cause, if the individual's status is the unsafe treatment status, at least one of an audible, visual, or vibratory alarm and revoke authorization for the actuator to administer glucagon, wherein the audible, visual, or vibratory alarm is indicative that the individual should reposition themself;
• determine a change in the individual's status from the unsafe treatment status to the safe treatment status in response to the audible, visual, or vibratory alarm;
• restore authorization to administer glucagon to the actuator in response to return to safe treatment status;
• confirm that the disease management system is coupled to the individual prior to causing administration of the glucagon to the individual;
• cause an alarm indicating to replace adhesive of the disease management system based at least in part on a determination that a conductance measurement does not satisfy a conductance threshold;
• inject the needle into the individual while the individual's status is the safe treatment status;
• and
• administer, while the individual's status is the safe treatment status, the glucagon to the individual using the actuator via the needle.